整合临床特征与生物标志物更新单基因糖尿病临床预测模型
研究采用贝叶斯重校准混合模型方法,开发了针对早发胰岛素治疗和非早发胰岛素治疗人群的两个预测模型,在病例对照数据(单基因糖尿病594例,非单基因糖尿病597例)中初始开发并利用UNITED研究(n=1,299)包含C肽和胰岛自身抗体的群体数据重校准,在独立人群队列(n=1,025)中外部验证。结果显示整合生物标志物显著提高判别能力,早发胰岛素治疗者ROC AUC达0.98,非早发者达0.86,外部验证判别良好,以≥5%概率阈值指导检测的单基因糖尿病阳性检测率为16-19%。
要点
- 整合C肽和胰岛自身抗体的预测模型判别能力优于仅用临床特征或仅用生物标志物。
- 早发胰岛素治疗者模型ROC AUC达0.98,非早发者达0.86,外部验证判别良好。
- 以≥5%概率阈值指导检测,单基因糖尿病阳性检测率为16-19%。
核心结论
- 整合临床特征与生物标志物的更新版单基因糖尿病概率计算器判别能力优于单独使用临床特征或生物标志物,可用于选择单基因糖尿病诊断检测对象。
研究设计与样本
- 采用贝叶斯重校准混合模型方法开发两个预测模型:早发胰岛素治疗者(1型糖尿病替代)和非早发胰岛素治疗者(2型糖尿病替代)。
- 使用病例对照数据(单基因糖尿病594例,非单基因糖尿病597例)进行初始模型开发(仅临床特征)。
- 利用UNITED研究(n=1,299)群体数据重校准,纳入生物标志物(C肽和胰岛自身抗体)。
- 在独立人群队列(n=1,025)中进行外部验证。
主要发现
- 早发胰岛素治疗者中,整合生物标志物的模型判别能力优于仅临床特征(ROC AUC 0.98 [95% CrI 0.95-0.98] vs. 0.80 [95% CrI 0.71-0.82],P < 0.001)或仅生物标志物(ROC AUC 0.96 [95% CI 0.95-0.97])。
- 非早发胰岛素治疗者中,计算器显示良好判别能力(ROC AUC 0.86 [95% CrI 0.85-0.88])。
- 两个模型校准良好,外部验证判别良好(早发者ROC AUC 0.98 [95% CrI 0.98-0.98],非早发者ROC AUC 0.92 [95% CrI 0.90-0.93])。
- 以≥5%概率阈值指导检测,单基因糖尿病阳性检测率为16-19%。
关键数值与推荐
- 早发胰岛素治疗者模型ROC AUC 0.98(95% CrI 0.95-0.98),仅临床特征0.80(95% CrI 0.71-0.82),仅生物标志物0.96(95% CI 0.95-0.97),P < 0.001。
- 非早发胰岛素治疗者模型ROC AUC 0.86(95% CrI 0.85-0.88)。
- 外部验证早发者ROC AUC 0.98(95% CrI 0.98-0.98),非早发者0.92(95% CrI 0.90-0.93)。
- ≥5%概率阈值指导检测的单基因糖尿病阳性检测率为16-19%。
临床怎么用
- 该在线计算器已可用,对诊断年龄≤35岁的白人欧洲裔糖尿病患者具有直接临床实用性。
- 可整合临床特征与生物标志物评估单基因糖尿病概率,指导遗传检测对象选择。
局限性
- 外部验证人群为白人欧洲裔糖尿病患者,其他人群适用性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Selecting appropriate individuals for monogenic diabetes genetic testing is challenging. We aimed to develop a new probability calculator, integrating clinical features and biomarkers, to aid identification of monogenic diabetes. RESEARCH DESIGN AND METHODS: We developed two prediction models (for early-insulin-treated, proxy for type 1 diabetes; and not-early-insulin-treated patients, proxy for type 2 diabetes) using a Bayesian recalibration mixture model approach. We used case-control data (monogenic diabetes = 594, non-monogenic diabetes = 597) for initial model development (clinical features only) and recalibrated to population data (Using pharmacogeNetics to Improve Treatment in Early-onset Diabetes [UNITED] study, n = 1,299) including biomarkers (C-peptide and islet autoantibodies). We externally validated the calculator in an independent population-based cohort (n = 1,025). RESULTS: For early-insulin-treated individuals, the model incorporating biomarkers improved discrimination over using clinical features only (receiver operating characteristic area under the curve [ROCAUC] 0.98 [95% credible interval [CrI] 0.95-0.98] vs. 0.80 [95% CrI 0.71-0.82], P < 0.001) or biomarkers alone (ROCAUC 0.96 [95% CI 0.95-0.97]). For not-early-insulin-treated participants, the calculator showed good discrimination (ROCAUC 0.86 [95% CrI 0.85-0.88]). Both models calibrated well and showed good discrimination in external validation (ROCAUC 0.98 [95% CrI 0.98-0.98] and 0.92 [95% CrI 0.90-0.93] for early- and not-early-insulin-treated individuals, respectively). Using a ≥5% probability threshold to guide testing achieved positive test rates for monogenic diabetes of 16-19%. CONCLUSIONS: We developed an updated monogenic diabetes probability calculator that integrates both clinical features and biomarkers, providing greater discrimination than using clinical features or biomarkers alone and providing appropriate measures for selecting individuals for monogenic diabetes diagnostic testing. This is now available as an online calculator and has immediate clinical utility for White European individuals diagnosed with diabetes ≤35 years.
引用
- Knupp J, Cardoso P, Young KG, et al. Updating a Clinical Prediction Model for Identifying Monogenic Diabetes to Include Both Clinical Features and Biomarkers. Diabetes Care. 2026. PMID: 41086125. doi:10.2337/dc25-1029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。